Therefore, these data suggest that IFN-Is reprogram tumor cell metabolism by facilitating ATP production via mitochondrial OXPHOS, and that tumor cells with OXPHOS genetic deficiency are resistant to CD47-SIRPα blockade therapy. This evidence concerns the gene SIRPA and neoplasm.